In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/switch-upadacitinib-vs-adalimumab-after-tnf-inhibitor-2026a1000dkx?src=rss
Author :
Publish date : 2026-04-29 09:00:00
Copyright for syndicated content belongs to the linked Source.